益气健脾化瘀方联合射波刀治疗胰腺癌疗效观察

目的观察益气健脾化瘀方联合射波刀治疗胰腺癌的临床疗效及安全性。方法将40例胰腺癌患者按1∶1比例随机分为治疗组20例和对照组20例。2组均进行射波刀治疗,对照组患者射波刀治疗结束后不再给予其他抗肿瘤药物治疗,治疗组患者同时给予益气健脾化瘀方连服3个月。观察2组患者治疗3个月后中医症状积分、肿瘤标志物(血清CEA、CA-199)水平、Karnofsky评分变化情况,统计2组近期疗效、肿瘤复发转移率及不良反应发生情况。结果治疗后,2组腹胀、胁痛、黄疸、纳呆、乏力评分和血清CEA、CA-199水平均明显低于治疗前(P均0. 05),且治疗组各项评分和血清CEA、CA-199水平均明显低于对照组(P均0. 05)。治疗近期有效率、Karnofsky评分升高稳定率均明显高于对照组(P均0. 05),肿瘤复发转移率和不良反应发生率均明显低于对照组(P均0. 05)。结论益气健脾化瘀方联合射波刀治疗胰腺癌近期疗效更好,且有较好的肿瘤局控作用,安全性好。     

基于网络药理学的左金丸治疗胃癌作用机制研究

目的基于网络药理学方法探讨左金丸治疗胃癌的作用机制。方法利用TCMSP数据库获得左金丸所含中药的化学成分及对应作用靶点基因,检索GeneCards和OMIM数据库获得疾病胃癌相关靶点基因,然后取两者的交集,得到左金丸作用于胃癌的预测靶基因;利用Cytoscape 3.7.1软件构建左金丸化合物-作用靶点-疾病三者相互关系网络,采用STRING数据库对左金丸作用于胃癌的预测靶基因进行蛋白互作网络分析,利用Cytoscape3.7.1软件的插件cytohubba筛选出关键靶基因,并利用ONCOMINE数据库分析关键靶基因在胃癌中的表达情况;利用在线工具DAVID进行GO功能富集分析并利用Cytoscape3.7.1软件的ClueGO插件进行KEGG通路富集分析。结果共筛选出左金丸作用于胃癌的预测靶基因68个,关键靶基因15个,这些关键基因在ONCOMINE数据库的胃癌样本和正常样本中的表达存在显著性差异。GO功能富集分析显示,左金丸作用于胃癌的预测靶基因主要涉及对有机物质的反应、细胞凋亡的负调控、细胞程序性死亡的负调控等生物过程;KEGG通路富集分析主要涉及癌症通路、p53信号通路、VEGF信号通路等。结论本研究初步揭示了左金丸治疗胃癌的主要作用靶点及多靶点、多维调控、协同作用、整体调节的作用机制,可为后续进一步深入研究其作用机制提供参考。     

全国名老中医蓝青强教授治疗失眠症的经验

蓝青强教授认为,失眠之症有虚实之分,实证多表现为气滞、瘀血、痰火郁结,虚证多表现为阴虚、气虚、血虚.正气虚弱是其发病的根本,脏腑功能失调是发病的基础,治疗应以补虚泻实、调整脏腑阴阳为大法.     

全国名老中医蓝青强教授治疗便秘证治经验

<正>便秘是临床常见病,其临床表现不尽相同,包括排便次数减少,粪便干结质硬,或排便不畅,费力困难等。据有关资料报道,慢性便秘发病率青年人为3%,中年人为8%,老年人为20%。便秘不仅为影响患者食欲及肠道之消化吸收,还会诱发或加重心脑血管病。便秘在《伤     

Effects of the Ganning Formula (肝宁方) on Liver Fibrosis in Patients With Chronic Hepatitis B

Objective: To investigate the clinical efficacy and safety of the Ganning formula (肝宁方) for the treatment of liver fibrosis in patients with chronic hepatitis B. Methods: In a multicenter, randomized, controlled clinical trial, 150 patients with liver fibrosis secondary to hepatitis B virus (HBV) infection were randomly assigned in equal numbers to receive either the Ganning formula (a Chinese herbal decoction; active treatment group) or oral entecavir (control group) for two 3-month courses. Patients were ...     

应用基因芯片分析牛磺酸对肝星状细胞基因表达的调控

牛磺酸具有多种生物学功能,近来的研究热点集中于其对肝脏损伤的保护作用,尤其是对肝纤维化的防治\[1-2\]。而肝星状细胞的活化是导致肝纤维化的重要原因。本实验应用基因芯片技术筛选牛磺酸作用于肝星状细胞后的差异表达基因,并对这些基因进行功能分类和代谢通路分析,进一步阐明牛磺酸抗肝纤维化的作用机制。     

扶正化瘀片治疗肝炎后肝硬化的研究

Objective: To investigate the efficacy and safety of the Fuzheng Huayu Tablet (扶正化瘀片, FZHYT), which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis (PHC). Methods: A multicenter, randomized, controlled clinical trial was conducted in 180 patients with PHC. The patients were randomly assigned using random numbers to a treatment group treated with FZHYT and a placebo group; the treatment course was 6 months for both groups. Overall response, adverse events (AEs), and the 2-year survival rate were assessed after treatment. Evaluations were made on changes in liver function, liver fibrosis, coagulation, hemodynamics, degrees of esophagogastric varices, ascites, quality of life (QOL), and scores of main symptoms. Results: The overall response was significantly higher in the treatment group than the placebo group (86.7% vs. 62.2%, P<0.01). Patients in both groups had signi?cant improvements in liver function [total bilirubin (TBIL), albumin (ALB)], liver fibrosis [hyaluronic acid (HA), type Ⅳ collagen (CⅣ)], coagulation [prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), and thrombin time (TT)], hemodynamics portal venous flow (PVF), and splenic vein flow (SVF) after treatment. Between-group comparisons showed that compared with the placebo group patients in the treatment group achieved significantly greater improvements in TBIL, ALB, HA, C Ⅳ, PT, APTT, PVF, SVF, time to ascites resolution, 2-year survival, QOL, and symptom scores (P<0.05 or P<0.01). There were no significant AEs during the treatment. Conclusions: FZHYT is effective and safe for the treatment of hepatic cirrhosis as it is associated with improved liver function, liver ?brosis, coagulation, portal hypertension state, QOL, 2-year survival rate, and fewer AEs.     

肝宁方对门脉高压模型肝脏微循环的影响

目的 观察肝宁方对门静脉高压模型大鼠肝脏微循环的影响,诠释其防治肝纤维化的疗效及抑制门静脉高压的机制.方法 用复合因素法制作肝硬化模型,60只Wistar大鼠随机分为空白对照组、模型组、肝宁方治疗组,每组20只.检测治疗前后大鼠肝脏血流量,肝功能、血清HA、PCⅢ、LN含量,观察肝脏微循环流速及肝组织病理结构.结果 与对照组比较,治疗组和模型组大鼠肝脏平均血流灌注量及肝微血管流速均有不同程度的下降,差异有显著性(P<0.01);与模型组比较,治疗组大鼠肝脏平均血流灌注量及肝微血管流速均有明显提高,且肝功能、血清HA、PCⅢ、LN含量及肝组织病理结构均得到明显改善,差异有显著性(P<0.05或P(0.01).结论 肝宁方具有抗肝纤维化作用.可以通过改善肝组织病理结构,提高模型肝脏血流灌注量及肝微循环流速,作用于门静脉高压形成的"后向血流"机制,从而降低门静脉压力.